6-氯喹唑啉-2,4-二酮 | 1640-60-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-氯喹唑啉-2,4-二酮
• 中文别名: 6-氯喹唑啉-2,4(1H,3H)-二酮
• 英文名称: 6-chloro-1,2,3,4-tetrahydroquinazoline-2,4-dione
• 英文别名: 6-chloroquinazoline-2,4(1H,3H)-dione；6-chloro-1H-quinazoline-2,4-dione；6-Chloroquinazolin-2,4-dione
• CAS: 1640-60-4
• 化学式: C₈H₅ClN₂O₂
• mdl: MFCD00030678
• 分子量: 196.593
• InChiKey: IGWJEWGQUFOVDP-UHFFFAOYSA-N

物化性质

• 熔点：
  360℃ (acetic acid )
• 密度：
  1.475±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloroquinazoline-2,4-dione
Synonyms: 6-chloroquinazoline-2,4(1H,3H)-dione

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloroquinazoline-2,4-dione
CAS number: 1640-60-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5ClN2O2
Molecular weight: 196.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯喹唑啉-2,4-二酮 在 N,N-二甲基苯胺 、 三乙胺 、 三氯氧磷 作用下， 反应 69.0h， 生成 N-benzyl-2,6-dichloroquinazolin-4-amine
  参考文献：
  名称：

  Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities

  摘要：

  Moderate cyclic GMP phosphodiesterase (cGMP-PDE, PDE V) inhibitor 2-phenyl-4-anilino-quinazoline (1) was identified utilizing MultiCASE assisted drug design (MCADD) technology. Modification of compound 1 was conducted at the 2-, 4-, and 6-positions of the quinazoline ring for enhancement of cGMP-PDE inhibitory activity. The 6-substituted 2-(imidazol-1-yl)-quinazolines are 1000 times more potent in in vitro PDE V enzyme assay than the well-known inhibitor zaprinast. The 6-substituted derivatives of 2-(3-pyridyl)quinazoline 84 and 2-(imidazol-1-yl)quinazoline 86 exhibited more than 1000-fold selectivity for PDE V over the other four PDE isozymes. In addition, cGMP-PDE inhibitors 64, 65, and 73 were found to have an additional property of thromboxane synthesis inhibitory activity.

  DOI：

  10.1021/jm00018a014
• 作为产物：
  描述：

  2-氨基-5-氯苯甲酸 在 sodium hydroxide 、 溶剂黄146 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 27.0h， 生成 6-氯喹唑啉-2,4-二酮
  参考文献：
  名称：

  含取代的喹唑啉-2,4-（1 H，3 H）-二酮的寡脱氧核苷酸的三链体稳定性

  摘要：

  通过形成Hoogsteen氢键，可以在双链核酸和第三链之间观察到三重螺旋结构。我们在此报告了在TA ∗ T三联体中使用喹唑啉-2,4-二酮衍生物替代胸腺嘧啶。描述了喹唑啉-2,4-二酮，5-氟和6-硝基取代的喹唑啉环的一氯衍生物的合成和表征。通过热变性研究达到了各种修饰的碱基促进三链体形成的能力。

  DOI：

  10.1016/s0040-4020(97)00564-4
• 作为试剂：
  描述：

  2-氨基-5-氯苯甲酸 、 溶剂黄146 、 Sodium cyanate 、 sodium hydroxide 在 水 、 6-氯喹唑啉-2,4-二酮 作用下， 以 水 为溶剂， 反应 16.5h， 以This resulted in 5 g (44%) of 6-chloroquinazoline-2,4(1H,3H)-dione as a white solid的产率得到6-氯喹唑啉-2,4-二酮
  参考文献：
  名称：

  COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

  摘要：

  本公开涉及化合物和方法，用于治疗与液体潴留或盐过载相关的疾病，如心力衰竭（特别是充血性心力衰竭）、慢性肾脏病、终末期肾脏病、肝病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂引起的液体潴留。本公开还涉及化合物和方法，用于治疗高血压。本公开还涉及化合物和方法，用于治疗胃肠道疾病，包括治疗或减轻与胃肠道疾病相关的疼痛。

  公开号：

  US20120263670A1

文献信息

• PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME
  申请人：——

  公开号：US20010006969A1

  公开（公告）日：2001-07-05

  A pyrimidine nucleus-containing compound represented by the formula (I): 1 wherein ring A represents the ring of the formula (a): 2 in which R 1 is a nitro group, an amino group, a substituted amino group or a halogen atom, or the ring of the formula (b) 3 in which R 1′ is the group such as an alkyl group or an alkenyl group; R 2 to R 5 independently represent the group such as an alkyl group or an alkenyl group; with the proviso that at least one of R 2 to R 5 is an alkenyl group, or acid addition salts thereof.

  化合物的中心含有嘧啶核，其化学式表示为（I）： 其中环A代表化学式（a）的环： 其中R1是硝基、氨基、取代氨基或卤素原子，或者是化学式（b）的环： 其中R1'是诸如烷基或烯基等基团；R2到R5独立地代表诸如烷基或烯基等基团；但至少R2到R5中的一个是烯基，或其酸盐。
• Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
  申请人：Fujirebio Inc.

  公开号：US06339089B2

  公开（公告）日：2002-01-15

  A pyrimidine nucleus-containing compound represented by the formula (I): wherein ring A represents the ring of the formula (a): in which R1 is a nitro group, an amino group, a substituted amino group or a halogen atom, or the ring of the formula (b): in which R1′ is the group such as an alkyl group or an alkenyl group; R2 to R5 independently represent the group such as an alkyl group or an alkenyl group; with the proviso that at least one of R2 to R5 is an alkenyl group, or acid addition salts thereof.

  化合物的结构式（I）表示为含有嘧啶核的化合物： 其中环A代表结构式（a）的环： 其中R1是硝基、氨基、取代氨基或卤素原子，或结构式（b）的环： 其中R1'是诸如烷基或烯基的基团；R2至R5独立地代表诸如烷基或烯基的基团；但至少R2至R5中的一个是烯基，或其酸盐。
• Bifunctional Ionic Liquids for the Multitask Fixation of Carbon Dioxide into Valuable Chemicals
  作者：Vitthal B. Saptal、Bhalchandra M. Bhanage

  DOI：10.1002/cctc.201501044

  日期：2016.1

  (i) cycloaddition reactions of CO2/CS2 with epoxides to form cyclic carbonates and 1,3‐oxathiolane‐2‐thiones, (ii) transesterification of cyclic carbonates with methanol to form dimethyl carbonate, and (iii) synthesis of quinazoline‐2,4(1 H,3 H)‐diones and quinazoline‐2,4(1 H,3 H)‐dithiones from 2‐aminobenzonitriles and CO2/CS2. The developed methodology is transition‐metal free, solvent free, and additive free. Remarkably

  合成了一系列特定任务的离子液体（IL），例如单离子，双离子和聚合物支持的离子液体。这些IL用作多任务有机催化剂，可通过一系列反应将二氧化碳转化为有价值的化学物质，包括（i）CO 2 / CS 2与环氧化物的环加成反应，形成环状碳酸酯和1,3-氧杂硫杂环戊烷-2-硫酮， （ii）与甲醇的环状碳酸酯的酯交换反应，以形成碳酸二甲酯，和（iii）喹唑啉-2,4（1合成 ħ，3  ħ） -二酮和喹唑啉-2,4（  ħ，3  ħ）从-dithiones 2-氨基苄腈和CO 2 / CS 2。开发的方法是无过渡金属，无溶剂和无添加剂的。值得注意的是，已开发的白介素可在多达七个连续的循环中进行回收。因此，使该协议绿色环保并具有成本效益。
• A Green, Facile, and One-pot Synthesis of 2,4-(1<i>H</i>,3<i>H</i>)-Quinazolinediones under Microwave Irradiations
  作者：Farzad Nikpour、Touraj Paibast

  DOI：10.1246/cl.2005.1438

  日期：2005.10

  Quinazoline-2,4-diones are of considerable interest due to their wide pharmacological properties. Here, we have described an environmentally friendly method for the one-pot synthesis of 2,4-(1H,3H)-quinazolinediones from the reaction of anthranilic acid derivatives with urea in H 2 O media under microwave irradiations. This method is simple, safe, and fast which produces high yield of products without

  由于其广泛的药理特性，喹唑啉-2,4-二酮引起了相当大的兴趣。在这里，我们描述了一种环境友好的方法，用于从邻氨基苯甲酸衍生物与尿素在 H 2 O 介质中在微波辐射下的反应中一锅合成 2,4-(1H,3H)-喹唑啉二酮。该方法简单、安全、快速，无需任何催化剂，产品收率高。
• OLIGONUCLEOTIDE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150376611A1

  公开（公告）日：2015-12-31

  The present invention provides an oligonucleotide having improved affinity for AGO2, and the like. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like) or formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like} at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3.

  本发明提供了一种具有改善对AGO2亲和力的寡核苷酸等。该寡核苷酸在其5'端具有由式(I)表示的核苷酸残基或核苷酸残基其中X 1 是氧原子或类似物，R 1 是式(IIA)（其中R 5A 是卤素或类似物，而R 6A 是氢原子或类似物）或式(IVA)（其中Y 3A 是氮原子或类似物，而Y 4A 是CH或类似物），或类似物，R 2 是氢原子、羟基、卤素或可选择地取代的较低烷氧基，而R 3 是氢原子或类似物}，并且该核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。

表征谱图